November 06, 2009
Istodax approved for cutaneous T-cell lymphoma
The ORRs in these two trials were similar (34% and 35% in Study 1 and Study 2, respectively) and CR rates were the same (6%). The median response duration was 15 months in Study 1 and 11 months in Study 2. Median time to first response was 2 months in both studies. Median time to CR was 6 months in Study 1 and 4 months in Study 2.
Istodax is expected to be available in January 2010.
For more information call (866) 223-7145 or visit www.istodax.com.